Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer
- 10 August 2006
- Vol. 107 (4) , 676-685
- https://doi.org/10.1002/cncr.22036
Abstract
Since 1997, when gemcitabine showed superior clinical benefit to single‐agent5‐fluorouracil, it has remained the standard of care for the treatment of advanced pancreatic cancer. Numerous new agents, both cytotoxic and targeted, have been tested against this standard. Some trials showed improved response rates or progression free survival, but there was no clear improvement in survival. For the current report, those trial results were reviewed in depth for methodology, endpoints, and study characteristics. More recent studies have shown progress. Studies with combinations of gemcitabine and capecitabine and with the epidermal growth factor receptor antagoinist, erlotinib, have demonstrated survival benefits. Currently, studies of combinations with oxaliplatin, bevacizumab, and cetuximab are ongoing. Other targeted therapies also are considered for future clinical trials. Based on a comprehensive review of past trials, a consensus on endpoints in the treatment of pancreatic cancer and an approach to new trials is presented. Cancer 2006. © 2006 American Cancer Society.Keywords
This publication has 32 references indexed in Scilit:
- Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic CancerJournal of Clinical Oncology, 2005
- HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management ForumThe Oncologist, 2005
- Gemcitabine and ISIS-2503 for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma: A North Central Cancer Treatment Group Phase II TrialJournal of Clinical Oncology, 2004
- Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response RateJournal of Clinical Oncology, 2004
- Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A Multicenter Phase II TrialJournal of Clinical Oncology, 2004
- Complications of MalignancyJournal of Clinical Oncology, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2003
- Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinomaCancer, 2002
- Inhibition of Growth and Metastasis of Human Pancreatic Cancer Growing in Nude Mice by PTK 787/ZK222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine KinasesCancer Biotherapy & Radiopharmaceuticals, 2001